Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta‐Analysis

Whether histamine H3 receptor antagonists (H3R‐ANTs)/inverse agonists (H3R‐IAs) provides benefit for the treatment of schizophrenia remains unclear. This meta‐analysis was conducted to address the above clinical question.

• Publication year

  2025

• Venue

  Neuropsychopharmacology Reports

• Publication date

  2025-06-26

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/npr2.70034PMID 40567153PMCID 12198695
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta‐Analysis

  2025cited by this paper
• Meta-analysis of the factor structure of the Scale for the Assessment of Negative Symptoms (SANS) and the Scale for the Assessment of Positive Symptoms (SAPS).

  2024cited by this paper
• Antipsychotic Drugs and Cognitive Function: A Systematic Review and Pairwise Network Meta-Analysis.

  2024cited by this paper
• Effects of Adjunctive Betahistine Therapy on Lipid Metabolism in Patients with Chronic Schizophrenia: A Randomized Double-Blind Placebo-Controlled Study

  2023cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders

  2022cited by this paper
• Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis

  2022cited by this paper
• The Economic Burden of Schizophrenia in the United States.

  2022influential reference
• pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

  2022cited by this paper
• Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan.

  2021cited by this paper
• High-Dose Betahistine Improves Cognitive Function in Patients With Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial

  2021influential reference
• Characterization of Models for Identifying Physical and Cognitive Frailty in Older Adults With Diabetes: Systematic Review and Meta-Analysis

  2020cited by this paper
• Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis

  2019cited by this paper
• Histamine H3 receptor antagonists/inverse agonists: Where do they go?

  2019cited by this paper
• Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis

  2018cited by this paper
• Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study

  2018cited by this paper
• Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases.

  2016cited by this paper
• Dose Equivalents for Antipsychotic Drugs: The DDD Method.

  2016cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain

  2016cited by this paper
• A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.

  2015cited by this paper
• Histamine H3 Receptor Antagonists for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

  2015cited by this paper
• Procognitive Properties of Drugs with Single and Multitargeting H3 Receptor Antagonist Activities

  2014cited by this paper
• A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia.

  2014cited by this paper
• The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.

  2014influential reference
• Psychopathological long‐term outcome of schizophrenia – a review

  2013cited by this paper
• Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.

  2013cited by this paper
• Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse

  2012cited by this paper
• Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine–betahistine combination

  2012influential reference
• Discovery of Histamine H3 Antagonists for the Treatment of Cognitive Disorders and Alzheimer's Disease

  2011cited by this paper
• Histamine in the regulation of wakefulness.

  2011cited by this paper
• Schizophrenia

  2009cited by this paper
• The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.

  2004cited by this paper
• Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

  2004cited by this paper
• How meta-analysis increases statistical power.

  2003cited by this paper
• UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults.

  2001cited by this paper
• Revision of the Brief Visuospatial Memory Test: Studies of normal performance, reliability, and validity.

  1996cited by this paper
• Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms.

  1995cited by this paper
• The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia.

  1989cited by this paper
• The Positive and Negative Syndrome Scale (PANSS): Rationale and Standardisation

  1989cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• Negative symptoms in schizophrenia

  1982cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• Development of a rating scale for primary depressive illness.

  1967cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper

• Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta‐Analysis

  2025cites this paper
• Comparative receptor pharmacology of antipsychotic drugs based on normalized binding affinity data and breadth of interaction.

  2025cites this paper
• Combination Lorcaserin and Betahistine Treatment Improves Cognitive Dysfunction and Dopaminergic Neuron Activity in a Rat Model of Diet-Induced Obesity

  2025cites this paper